Nashik FDA Cancels Shivnath Ayurveda's Licence

The Food and Drug Administration (FDA) in Nashik has permanently cancelled the manufacturing licence of Shivnath Ayurveda Product Company. This decision comes after the Maharashtra Andhashraddha Nirmoolan Samiti (ANiS) filed a complaint against the company, alleging illegal drug manufacturing and quackery.

The complaint was filed by Advocate Ranjana Pagar-Gawande, State Secretary of ANiS, who had earlier lodged a complaint against alleged godman Rajendra Gadge Baba. Dr Mohan Puri, owner of Shivnath Ayurveda, was named as a co-accused in that case. It was alleged that Dr Puri was supplying unapproved medicines at the gatherings of Rajendra Gadge Baba.

FDA officials inspected the manufacturing unit in Jaigaon and found serious violations, including non-compliance with pharmaceutical manufacturing standards and breaches of the Drugs and Cosmetics Act. A show-cause notice was issued to Dr Puri, and after a hearing, the FDA concluded that the violations were serious and passed an interim order cancelling the company's manufacturing licence.

The decision was communicated to Advocate Pagar-Gawande through a letter issued by the Assistant Commissioner (Drugs) and Licensing Authority, FDA Nashik Division-II. Dr Mohan Puri is alleged to be a close associate of Rajendra Gadge Baba and is suspected of supplying medicines to various self-styled godmen.

The ANiS has been actively working against alleged quacks across Maharashtra, following the Bharat Kharat case. The organisation has filed complaints against several individuals, including Rajendra Gadge Baba. The cancellation of Shivnath Ayurveda's manufacturing licence is a significant step in the fight against illegal drug manufacturing and quackery.

The FDA's action is expected to have a positive impact on public health, as it will prevent the manufacture and sale of unapproved medicines. The ANiS has welcomed the decision and has urged the authorities to take similar action against other alleged quacks.

The case highlights the importance of regulatory bodies in ensuring public health and safety. The FDA's inspection and subsequent action against Shivnath Ayurveda demonstrate the effectiveness of the regulatory framework in preventing the manufacture and sale of unapproved medicines.

In conclusion, the cancellation of Shivnath Ayurveda's manufacturing licence is a significant step in the fight against illegal drug manufacturing and quackery. The FDA's action is expected to have a positive impact on public health, and the ANiS has urged the authorities to take similar action against other alleged quacks.

The decision also highlights the importance of advocacy groups like ANiS, which work tirelessly to expose and prevent illegal activities. The organisation's efforts have led to the cancellation of Shivnath Ayurveda's manufacturing licence, and it is expected to continue its work in the fight against quackery and illegal drug manufacturing.

The cancellation of Shivnath Ayurveda's manufacturing licence is a significant development in the fight against quackery and illegal drug manufacturing. It is expected to have a positive impact on public health and safety, and it highlights the importance of regulatory bodies and advocacy groups in preventing such activities.

The FDA's action against Shivnath Ayurveda is a testament to the effectiveness of the regulatory framework in preventing the manufacture and sale of unapproved medicines. It is expected to serve as a deterrent to other companies and individuals involved in similar activities, and it is a significant step in the fight against quackery and illegal drug manufacturing.

In the end, the cancellation of Shivnath Ayurveda's manufacturing licence is a victory for public health and safety. It is a reminder of the importance of regulatory bodies and advocacy groups in preventing illegal activities, and it is expected to have a positive impact on the lives of millions of people in Maharashtra and beyond.